Funding

News

Hand in glove holding Petri plate with bacteria Steptococcus Phaemolifticus G, Streptococcus Agalactiae, Streptococcus Phaemolifticus

Minervax raises €47.4m in Series B funding round for GBS sho...

Denmark’s MinervaX has raised €47.4 million (around $56 million) in a Series B funding round to take its novel group B streptococcus (GBS) vaccine into mid-stage clinical trials.

News

Sinovac raises $515m to boost production of potential COVID-...

China’s Sinovac has raised $515 million to increase its distribution and production capacity as clinical development of its potential coronavirus vaccine nears conclusion.

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

Swiss start-up Noema raises $59m to develop neurology drugs ...

Swiss biotech Noema has raised 54 million Swiss francs ($59m) to develop four neurological disorder drugs licensed in from Roche.

News

Sidekick Health raises $20m to fund digital therapeutics exp...

Gamified digital therapeutics firm Sidekick Health has raised $20 million in a Series A funding round, which it plans to use to develop its product offering.

News

SparingVision raises €44.5m for retinitis pigmentosa gene th...

French biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare ocular disease.

News

US snaps up first supplies of Regeneron’s COVID-19 antibody

Hard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has agreed a deal to ramp up manufacturing – and claim the first

Minervax raises €47.4m in Series B funding round for GBS sho...

Sinovac raises $515m to boost production of potential COVID-...

Swiss start-up Noema raises $59m to develop neurology drugs ...

Sidekick Health raises $20m to fund digital therapeutics exp...

SparingVision raises €44.5m for retinitis pigmentosa gene th...

US snaps up first supplies of Regeneron’s COVID-19 antibody

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

Funding

Editor's Picks